180 Life Sciences Corp represents the values of innovation, dedication, and patient-centric care. With a corporate philosophy focused on advancing solutions for inflammatory diseases and fibrosis, the company is committed to improving the lives of patients worldwide. Through extensive research and development, 180 Life Sciences Corp aims to develop groundbreaking therapies and medical interventions that address unmet medical needs. This dedication to scientific excellence and patient well-being drives the company's pursuit of novel treatments and advancements in the field of life sciences.

180 Life Sciences Corp is primarily present in the following countries and regions: United States of America (USA), Europe, and Canada.

180 Life Sciences Corp has achieved several significant milestones. Firstly, the company successfully completed its reverse merger with KBLM Acquisition Corp., enabling it to become a publicly traded entity. Additionally, 180 Life Sciences Corp has made notable progress in its research and development activities, particularly in the areas of inflammation and fibrosis. The company has collaborated with world-renowned academic institutions and has established strong partnerships with leading experts in the field. Furthermore, 180 Life Sciences Corp has expanded its pipeline of potential therapeutics, advancing novel drug candidates that have shown promising preclinical results. These achievements highlight the company's dedication to developing innovative solutions for various diseases and improving patient outcomes.

180 Life Sciences Corp is a pharmaceutical company focused on developing and commercializing innovative therapies for inflammatory diseases and fibrosis. Founded in [year], the company has a strong dedication to improving patient outcomes by targeting the underlying mechanisms of these conditions. With a robust pipeline of potential treatments, including clinical-stage drug candidates, 180 Life Sciences Corp strives to address unmet medical needs and make a positive impact in the field of healthcare. Through extensive research and collaborations, the company aims to revolutionize treatment options and enhance the quality of life for individuals suffering from inflammatory diseases and fibrosis.

Some of the main competitors of 180 Life Sciences Corp in the market include biopharmaceutical companies such as AbbVie Inc., Johnson & Johnson, Pfizer Inc., and Novartis AG. These companies also focus on developing and commercializing innovative therapies in the healthcare sector. However, 180 Life Sciences Corp distinguishes itself through its dedication to advancing novel treatments for inflammatory diseases and fibrosis conditions. With its unique research and development efforts, 180 Life Sciences Corp aims to stand out in the market and provide innovative solutions for patients worldwide.

180 Life Sciences Corp is primarily active in the pharmaceutical and biotechnology industries.

The business model of 180 Life Sciences Corp is focused on the development and commercialization of novel pharmaceutical products in the field of inflammatory diseases and fibrosis. The company aims to address unmet medical needs by identifying and advancing potential therapies through rigorous research and clinical trials. With a specialized focus on the development of targeted therapies, 180 Life Sciences Corp strives to improve patient outcomes and quality of life. By leveraging scientific expertise and strategic collaborations, the company aims to bring innovative and effective treatments to market, benefiting both patients and stakeholders in the healthcare industry.

Poměr 180 Life Sciences P/E je -0,01.

Koeficient 180 Life Sciences tržních hodnot je 0,11.

AlleAktien kvalitní skóre pro 180 Life Sciences je 3/10.

očekávané 180 Life Sciences obrat je 8,47 mil. USD.

očekávané 180 Life Sciences zisk je -123,81 mil. USD.

180 Life Sciences Corp is a biopharmaceutical company based in the UK that develops innovative technologies for the treatment of inflammatory diseases. The company aims to significantly improve the quality of life for patients with chronic inflammatory conditions such as arthritis and fibromyalgia. The company follows a diversified business model that focuses on several areas. The main areas of the company include: - Research and development: 180 Life Sciences Corp conducts extensive research and development to develop innovative and effective drugs for the treatment of inflammatory diseases. The company has made significant progress in the areas of drug design and drug delivery systems. - Collaboration with strategic partners: The company forms targeted partnerships with leading pharmaceutical companies to enable commercialization of its products. 180 Life Sciences Corp collaborates closely with the University of Oxford and the Ferraresi Foundation to develop new technologies and conduct research activities. - Licensing: The company licenses its technologies and products to other companies. An example of this is the licensing of its technology for the production of transdermal patches to the pharmaceutical company Procter & Gamble. The products currently being developed by 180 Life Sciences Corp target the treatment of inflammatory diseases. The company's leading drug is a synthetic cannabidiol (CBD) product called SLS-002. This product is suitable for the treatment of inflammation and pain associated with arthritis and fibromyalgia. The company is also developing an inhalation device for the administration of cannabinoids. This device is intended to deliver the medication quickly and accurately to the lungs, increasing effectiveness and reducing necessary dosages. 180 Life Sciences Corp has also developed a technology for the production of transdermal patches. These patches are capable of delivering active ingredients directly through the skin, ensuring more effective absorption of the medication into the body. The company has entered into a licensing agreement with Procter & Gamble to utilize the transdermal patch technology. Overall, 180 Life Sciences Corp follows a promising business model based on a wide range of technologies and products for the treatment of inflammatory diseases. The company is working hard to further develop its technologies and establish new partnerships with other companies to bring its products to market.

180 Life Sciences vyplácí dividendu ve výši 0 USD rozdělenou do výplat během roku.

Dividenda pro 180 Life Sciences momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti 180 Life Sciences je US68236V1044.

WKN společnosti 180 Life Sciences je A2QJX5.

Ticker společnosti 180 Life Sciences je ATNF.

Během posledních 12 měsíců vyplatila společnost 180 Life Sciences dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že 180 Life Sciences vyplatí dividendu ve výši 0 USD.

Výnos z dividend společnosti 180 Life Sciences aktuálně činí .

180 Life Sciences vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

180 Life Sciences vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 USD. To odpovídá dividendovému výnosu 0 %.

180 Life Sciences je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě 180 Life Sciences ve výši 0 USD, zaznamenané 19. 7. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 19. 7. 2024.

Poslední dividendy byly vyplaceny dne 19. 7. 2024.

V roce 2023 společností 180 Life Sciences bylo vyplaceno 0 USD ve formě dividend.

Dividendy společnosti 180 Life Sciences jsou vypláceny v USD.